Brii Biosciences Limited (HKG:2137)
Hong Kong
· Delayed Price · Currency is HKD 2.090
+0.140 (7.18%)
May 2, 2025, 4:08 PM HKT
Brii Biosciences Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Net Income | -508.16 | -174.83 | -484.31 | -4,164 | -1,190 | Upgrade
|
| Depreciation & Amortization | 8.45 | 15.27 | 16.63 | 17.26 | 14.21 | Upgrade
|
| Other Amortization | 0.4 | 0.4 | 0.4 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 90.35 | 5.43 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 109.69 | -136.24 | -31.69 | -44.8 | 15.02 | Upgrade
|
| Stock-Based Compensation | 16.05 | 64.22 | 77.93 | 79.37 | 29.48 | Upgrade
|
| Provision & Write-off of Bad Debts | 50.79 | - | - | - | - | Upgrade
|
| Other Operating Activities | -90.05 | -247.54 | 1.75 | 3,566 | 255.72 | Upgrade
|
| Change in Accounts Payable | -17.27 | -81.46 | -58.14 | -286.62 | 477.59 | Upgrade
|
| Change in Unearned Revenue | -33.69 | -6.13 | -3.21 | -21.94 | 17.88 | Upgrade
|
| Change in Other Net Operating Assets | 0.55 | -33.14 | -15.65 | -25.18 | -24.02 | Upgrade
|
| Operating Cash Flow | -372.89 | -594.01 | -496.28 | -879.46 | -403.72 | Upgrade
|
| Capital Expenditures | -3.23 | - | - | -1.03 | - | Upgrade
|
| Sale (Purchase) of Intangibles | - | -49.61 | -139.29 | - | - | Upgrade
|
| Investment in Securities | 888.37 | -225.92 | -1,333 | -479.65 | -44.61 | Upgrade
|
| Other Investing Activities | 10.33 | 171.17 | 38.65 | 4.92 | 0.96 | Upgrade
|
| Investing Cash Flow | 895.47 | -104.35 | -1,433 | -475.76 | -43.65 | Upgrade
|
| Long-Term Debt Repaid | -6.87 | -9.5 | -8.96 | -9.75 | -6.79 | Upgrade
|
| Net Debt Issued (Repaid) | -6.87 | -9.5 | -8.96 | -9.75 | -6.79 | Upgrade
|
| Issuance of Common Stock | 0.05 | 0.18 | 7.45 | 2,325 | 0.14 | Upgrade
|
| Repurchase of Common Stock | -0.22 | -1.16 | -0.68 | - | - | Upgrade
|
| Other Financing Activities | -2.37 | -0.49 | -0.85 | -87.81 | -4.74 | Upgrade
|
| Financing Cash Flow | -9.41 | -10.98 | -3.04 | 3,230 | 657 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.54 | 8.42 | 267.97 | -54.79 | -55.03 | Upgrade
|
| Net Cash Flow | 513.72 | -700.92 | -1,665 | 1,820 | 154.61 | Upgrade
|
| Free Cash Flow | -376.12 | -594.01 | -496.28 | -880.49 | -403.72 | Upgrade
|
| Free Cash Flow Margin | -683.96% | -1054.67% | -405.86% | -951.45% | -491.03% | Upgrade
|
| Free Cash Flow Per Share | -0.52 | -0.82 | -0.69 | -2.00 | -2.11 | Upgrade
|
| Cash Interest Paid | 2.37 | 0.49 | 0.85 | 1.18 | 1.67 | Upgrade
|
| Levered Free Cash Flow | -250.93 | -446.87 | -438.46 | -603.47 | -37.34 | Upgrade
|
| Unlevered Free Cash Flow | -249.45 | -446.56 | -437.93 | -602.74 | -36.3 | Upgrade
|
| Change in Net Working Capital | 21.88 | 139.5 | 72.45 | 316.79 | -480.62 | Upgrade
|
Updated Mar 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.